Literature DB >> 19709778

Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile.

S W Pawlowski, L Archbald-Pannone, R J Carman, C Alcantara-Warren, D Lyerly, C W Genheimer, D N Gerding, R L Guerrant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19709778      PMCID： PMC2743747          DOI： 10.1016/j.jhin.2009.05.013

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN： 0195-6701            Impact factor:   3.926


× No keyword cloud information.
  6 in total

1.  Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe.

Authors:  Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

2.  An epidemic, toxin gene-variant strain of Clostridium difficile.

Authors:  L Clifford McDonald; George E Killgore; Angela Thompson; Robert C Owens; Sophia V Kazakova; Susan P Sambol; Stuart Johnson; Dale N Gerding
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

3.  A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes.

Authors:  M Catherine McEllistrem; Robert J Carman; Dale N Gerding; C W Genheimer; L Zheng
Journal:  Clin Infect Dis       Date:  2004-12-15       Impact factor: 9.079

4.  A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use.

Authors:  Carlene A Muto; Marian Pokrywka; Kathleen Shutt; Aaron B Mendelsohn; Kathy Nouri; Kathy Posey; Terri Roberts; Karen Croyle; Sharon Krystofiak; Sujata Patel-Brown; A William Pasculle; David L Paterson; Melissa Saul; Lee H Harrison
Journal:  Infect Control Hosp Epidemiol       Date:  2005-03       Impact factor: 3.254

5.  Fecal lactoferrin, interleukin-1beta, and interleukin-8 are elevated in patients with severe Clostridium difficile colitis.

Authors:  T S Steiner; C A Flores; T T Pizarro; R L Guerrant
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

6.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity.

Authors:  Jacques Pépin; Louis Valiquette; Marie-Eve Alary; Philippe Villemure; Annick Pelletier; Karine Forget; Karine Pépin; Daniel Chouinard
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262
  6 in total
  8 in total

1.  Lactic acid production by Streptococcus thermophilus alters Clostridium difficile infection and in vitro Toxin A production.

Authors:  Glynis L Kolling; Martin Wu; Cirle A Warren; Evelyn Durmaz; Todd R Klaenhammer; Michael P Timko; Richard L Guerrant
Journal:  Gut Microbes       Date:  2012-08-16

Review 2.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

3.  Clostridium difficile ribotype 027 is most prevalent among inpatients admitted from long-term care facilities.

Authors:  L R Archbald-Pannone; J H Boone; R J Carman; D M Lyerly; R L Guerrant
Journal:  J Hosp Infect       Date:  2014-07-30       Impact factor: 3.926

4.  Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality.

Authors:  J H Boone; L R Archbald-Pannone; K N Wickham; R J Carman; R L Guerrant; C T Franck; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-22       Impact factor: 3.267

5.  Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens.

Authors:  Sunny Park; Miseon Park; Fatemeh Rafii
Journal:  BMC Microbiol       Date:  2013-03-01       Impact factor: 3.605

6.  Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile.

Authors:  Monica Viladomiu; Raquel Hontecillas; Mireia Pedragosa; Adria Carbo; Stefan Hoops; Pawel Michalak; Katarzyna Michalak; Richard L Guerrant; James K Roche; Cirle A Warren; Josep Bassaganya-Riera
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

7.  Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection.

Authors:  J H Boone; J R DiPersio; M J Tan; S-J Salstrom; K N Wickham; R J Carman; H R Totty; R E Albert; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-06-18       Impact factor: 3.267

8.  Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study.

Authors:  Andrew Swale; Fabio Miyajima; Paul Roberts; Amanda Hall; Margaret Little; Mike B J Beadsworth; Nick J Beeching; Ruwanthi Kolamunnage-Dona; Chris M Parry; Munir Pirmohamed
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.